Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



THERANEXUS announces the formation of its scientific Board

04/06/2019
Download PDF File (375 Ko)

THERANEXUS to present new data on neuron-glia interactions at two scientific events

23/05/2019
Download PDF File (380 Ko)

THERANEXUS announces issuance of Chinese patent covering its drug candidate THN102

24/04/2019
Download PDF File (381 Ko)

THERANEXUS provides 2018 full-year results and update on activities

17/04/2019
Download PDF File (416 Ko)

THERANEXUS announces research collaboration with IRISA using artificial intelligence technologies to enhance therapeutic targeting of neuroglial interactions

09/04/2019
Download PDF File (376 Ko)

December, 2019 : CF&B Midcap Event, Geneva (exact date to be confirmed)

October 14 & 15, 2019 : CF&B European MidCap Event, Paris

September 20, 2019 : CF&B Midcap Event, Amsterdam

June 18 & 19, 2019 : CF&B Spring European Midcap, Paris